← Research library

Peptide, preparation and pharmaceutical composition — US6248716B1

Patent disclosure · 2001

What the patent describes
Broad peptide-analogue patent with multiple animal experiments; the selected numerical example concerns cattle growth.
Reported evidence
The Sedatin patent documents Arg–Tyr–D-Ala–Phe–Gly and related peptide chemistry. Related scaffold claims in RU2067000C1 do not establish that every possible A-number was synthesized or tested.

Cattle weight gain · 233.2 ± 2.4 kg treated versus 189.0 ± 2.7 kg control; 12 animals/group · Starting weights 72.3 ± 0.9 and 72.2 ± 1.1 kg; not human therapeutic benefit

Reported patent results

Reported findings

A preparation tested in the patent was associated with greater weight gain in a small animal-production comparison.

Broad peptide-analogue patent with multiple animal experiments; the selected numerical example concerns cattle growth.

Population or model Broad peptide-analogue patent with multiple animal experiments; the selected numerical example concerns cattle growth.

Results · Table 13: cattle growth comparison; broad candidate scope explicitly limited.
MeasureResultComparison, timing and statistics
Cattle weight gain233.2 ± 2.4 kg treated versus 189.0 ± 2.7 kg control; 12 animals/groupStarting weights 72.3 ± 0.9 and 72.2 ± 1.1 kg; not human therapeutic benefit
Daily gain752 ± 17.3 g/day versus 610 ± 15.8 g/daySame cattle example; observation duration not independently entered

The broad patent contains different peptide constructs and experiments. This animal example cannot establish a human anti-stress effect or be assigned to every Sedatin/dermorphin analogue.

Source for these results ↗ · Reviewed 2026-11-06

Patent claims and provenance

Use. Stress-related method claims involving defined peptide analogues in the sedatin/dermorphin research trail; sequence and terminal modifications limit transfer to other analogues.

A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.

Publication
US6248716B1 ↗ · 2001-06-19
Earliest priority / filing
1995-06-27 / 1999-05-27
Original applicant / assignee
Immunotech Developments Inc
Indexed status
Expired - Lifetime · checked 2026-11-06
Patent family
27082120 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Peptide, a method for its preparation and a pharmaceutical composition containing the peptide

Inventors: Vladislav I. Deigin; Elena P. Yarova.

US6248716B1

Original patent PDF ↗

Patent collection and status interpretation →

Study limitations and source details

Study limitations

  • No clinical benefit or regulatory approval inferred from patent grant.

Source details

Selected original-source text checked; full methodological review pending.

Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.

Sources checked

Citation

Patent / reported experimentsFull text available

Author unconfirmed. Peptide, preparation and pharmaceutical composition — US6248716B1 Primary source linked above

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards